19 May 2020

UK-headquartered AstraZeneca is in discussions with international governments and organisations for Covid-19 vaccine candidate manufacturing deals similar to its agreement with the UK government, according to Reuters. The organisations in question are said to include the Coalition for Epidemic Preparedness Innovations (CEPI) and the Global Alliance for Vaccines and Immunisation (Gavi, the Vaccine Alliance).

India-based Cipla has plans to explore the use of multi-drug combination, including Gilead Sciences‘ remdesivir, for the treatment of Covid-19. In an interview with Livemint news agency, Cipla chief financial officer Kedar Upadhye said that the company intends to assess a combination of zinc, hydroxychloroquine, azithromycin, lopinavir-ritonavir and favipiravir, among other drugs.

Johnson & Johnson (J&J) has signed an agreement with contract development and manufacturing organisation (CDMO) Vibalogics for the manufacture of clinical trial material for a Covid-19 vaccine candidate being developed by J&J unit Janssen. The deal will see Vibalogics produce multiple batches of the vaccine candidate at its facility in Cuxhaven, Germany.

The European Union may fast track authorisation for the sale of Gilead‘s remdesivir as a potential Covid-19 treatment, said Reuter citing the European Medicines Agency (EMA) head. A conditional approval for the drug is expected in the coming days. The EMA has already called for the compassionate use of the drug for Covid-19 patients

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.